Resources
12 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 7/28/2021 (updated 4/2/2024)
The suggested tools and resources herein address the need for agencies to support frontline service providers following exposure to an overdose fatality. Frontline service providers may include any staff members that interact directly with populations that are at greater risk for experiencing overdose. The suggestions throughout the document should be implemented in keeping with agency-based policies and procedures for staff support. Introducing these strategies into the workplace can foster greater well-being among those staff members most vulnerable to trauma and distress.
The goal of these suggestions is to promote well-being in the workplace for those most vulnerable to trauma, stress and grief. To achieve this, outlined below are principles for agencies to incorporate into their organization, how to acknowledge death in the moment, approaches to coping with strong emotions, the importance of building a support system, and the process of grief.
Posted 6/17/2021 (updated 4/2/2024)
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.
Objective:To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 4/19/2021 (updated 4/5/2024)
The present article reviews whether available efficacy and safety data support the pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorders (SUD). Arguments for and against treating adult ADHD with active SUD are discussed
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 9/1/2020 (updated 3/29/2024)
This toolkit is intended to give prescribers a broad overview of medication utilization management techniques and describe ways that prescribers can facilitate patient access to needed medications. It focuses on prescribed medications that are filled by retail pharmacies; it does not cover the processes for methadone or specialty pharmacy products, such as injectable or implantable medications, all of which are commonly covered by a patient’s medical benefit rather than their pharmacy benefit.
Posted 7/24/2020 (updated 3/28/2024)
This final rule makes changes to the Department of Health and Human Services’ (HHS) regulations governing the Confidentiality of Substance Use Disorder Patient Records. These changes were prompted by the need to continue aligning the regulations with advances in the U.S. health care delivery system, while retaining important privacy protections for individuals seeking treatment for substance use disorders (SUDs).
Posted 7/16/2020 (updated 3/28/2024)
The information in this document was guided by the vision of the U.S. Department of Health and Human Services’ Office on Women’s Health and lessons learned from a 3-year reentry enhancement project conducted across 3 different reentry organizations. The participating pilot sites were the Resonance Center for Women, Inc., the College and Community Fellowship, and the Institute for Health and Recovery . Using the information compiled through this project, this guide was created by the Substance Abuse and Mental Health Services Administration’s GAINS Center for Behavioral Health and Justice Transformation.
Posted 6/30/2020 (updated 3/28/2024)
Representing 25 years of empirical study on addiction, pharmacology, behavioral health, and criminal justice, these Standards are the foundation upon which all adult drug courts must operate.